2 results
Approved WMOCompleted
Primary• To assess the effects of RVT-101 versus placebo on global function as measured by the Clinician*s Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) after 24 weeks of treatment• To assess the effects of RVT-101 versus…
Approved WMORecruiting
To demonstrate superiority in the metastasis-free survival (MFS) of men with high risk NM-CRPC treated with apalutamide versus placeboSecondary Objective:To compare the overall survival (OS) of men with high risk NM-CRPC treated with apalutamide…